title: Half-dose recombinant tissue plasminogen activator treatment in venous thromboembolism.
abstract: BACKGROUND
  Pulmonary embolism (VTE) comes in different degrees of severity from massive pulmonary embolism to nonmassive pulmonary embolism with no symptoms or hypoxia. Thrombolytic therapy is a lifesaver especially for patients who are in the high-risk group. In this study, we aimed at evaluating symptoms and clinical and laboratory findings in patients who had a diagnosis of massive or submassive VTE and treated with 50-mg recombinant tissue plasminogen activator (rt-PA) per hour for various problems as opposed to the standard dose, which is 100 mg every 2 hours.
  
  
  METHODS
  Forty-six patients with a diagnosis of massive or submassive VTE who received thrombolytic therapy were evaluated retrospectively. Twenty-three patients who were treated with 50-mg rt-PA per hour were included in the study group. On the other hand, 23 patients who were treated with 100 mg of intravenous infusion of rt-PA every 2 hours were included in the control group. Echocardiographic assessment of the right ventricular size, systolic pulmonary artery pressure (sPAP), oxygen saturation, systemic arterial pressure, and heart rate before the thrombolytic therapy and in the first 24 hours after the administration of therapy were checked and noted in both of the groups.
  
  
  RESULTS
  No significant difference was found between the 2 groups with regard to demographic data, Wells scores, type of embolism, average symptom duration, sPAP, and oxygen saturation. Differences in recovery, as inferred from vital symptoms and sPAP measurements, were not significant between the 2 groups.
  
  
  CONCLUSIONS
  Lower-dose thrombolytic therapy showed similar efficacy versus the standard dose in VTE. Thrombolytic therapy is a life-saving treatment in massive VTE. Furthermore, a harm/benefit analysis may lead to the administration of half-dose therapy in selected cases when it is contraindicated for various reasons.
authors.affiliation: From the *Department of Chest Diseases, Faculty of Medicine, Yıldırım Beyazit University, Ankara, Turkey; and †Department of Chest Diseases, Atatürk Training and Research Hospital, Ankara, Turkey.
authors.forename: H
authors.initials: H
authors.lastname: Canan Hasanoğlu
authors.forename: Habibe
authors.initials: H
authors.lastname: Hezer
authors.forename: Ayşegül
authors.initials: A
authors.lastname: Karalezli
authors.forename: Emine
authors.initials: E
authors.lastname: Argüder
authors.forename: Hatice
authors.initials: H
authors.lastname: Kiliç
authors.forename: Ayşegül
authors.initials: A
authors.lastname: Şentürk
authors.forename: Mükremin
authors.initials: M
authors.lastname: Er
authors.forename: Ayşe Nur
authors.initials: AN
authors.lastname: Soytürk
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D010959:Tissue Plasminogen Activator